We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights ConocoPhillips SAP, CSX, Alnylam Pharmaceuticals and NVR
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 7, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: ConocoPhillips (COP - Free Report) , SAP SE (SAP - Free Report) , CSX Corp. (CSX - Free Report) , Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) and NVR, Inc. (NVR - Free Report)
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for ConocoPhillips, SAP and CSX
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including ConocoPhillips, SAP SE and CSX Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
ConocoPhillips shares have gained +43.4% over the past year against the Zacks Oil and Gas - Integrated U.S. industry's gain of +45.9%. The Zacks analyst believes that significant opportunities are there for the firm in the Bakken Shale, where it owns about 750 undrilled locations that could provide access to huge reserves.
Notably, the company has revised its expected 2022 return of capital to shareholders upward to $10 billion, reflecting an increase from the prior-mentioned $8 billion. Also, the company's balance sheet is significantly less leveraged than the industry it belongs to.
However, ConocoPhillips is highly exposed to oil price fluctuations, which is make things challenging for the company. Also, it has been generating lower dividend yield than the composite stocks belonging to the energy sector over the past few years.
SAP shares have declined -39.6% over the past year against the Zacks Computer - Software industry's decline of -15.4%. The Zacks analyst believes that suspension of Russian operations amid the ongoing Ukraine war is expected to affect both the company's revenues and non-IFRS operating profit in the near term.
Weak uptake of software licenses and support offerings remains a headwind. Stiff competition and increasing costs to enhance cloud-based offerings is likely to exert pressure on the company's profitability as well.
However, SAP's performance is gaining from strength in its cloud business, especially the new Rise with SAP solution. Momentum in SAP's Business Process Intelligence platform, particularly the S/4HANA solutions along with steady traction witnessed in SuccessFactors Employee Central, Ariba and Fieldglass, Qualtrics and other cloud-based offerings is noteworthy.
Shares of CSX have declined -13.6% over the past year against the Zacks Transportation – Rail industry's decline of -9.4%. The Zacks analyst believes that supply-chain disturbances are hurting the company's operations. Weakness in the merchandise segment due to lower automotive volumes is concerning. High costs, primarily due to escalating fuel expenses, pose a threat to CSX's bottom line. CSX's high capital expenditures are also worrisome.
However, CSX is benefiting from higher export coal volumes, domestic intermodal shipments and favorable pricing. With the demand scenario expected to remain strong, despite the current market bloodbath, management anticipates double-digit growth in operating income and revenues for 2022 from the respective year-ago reported figures.
Other noteworthy reports we are featuring today include Alnylam Pharmaceuticals, Inc., and NVR, Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights ConocoPhillips SAP, CSX, Alnylam Pharmaceuticals and NVR
For Immediate Release
Chicago, IL – July 7, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: ConocoPhillips (COP - Free Report) , SAP SE (SAP - Free Report) , CSX Corp. (CSX - Free Report) , Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) and NVR, Inc. (NVR - Free Report)
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for ConocoPhillips, SAP and CSX
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including ConocoPhillips, SAP SE and CSX Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
ConocoPhillips shares have gained +43.4% over the past year against the Zacks Oil and Gas - Integrated U.S. industry's gain of +45.9%. The Zacks analyst believes that significant opportunities are there for the firm in the Bakken Shale, where it owns about 750 undrilled locations that could provide access to huge reserves.
Notably, the company has revised its expected 2022 return of capital to shareholders upward to $10 billion, reflecting an increase from the prior-mentioned $8 billion. Also, the company's balance sheet is significantly less leveraged than the industry it belongs to.
However, ConocoPhillips is highly exposed to oil price fluctuations, which is make things challenging for the company. Also, it has been generating lower dividend yield than the composite stocks belonging to the energy sector over the past few years.
(You can read the full research report on ConocoPhillips here >>>)
SAP shares have declined -39.6% over the past year against the Zacks Computer - Software industry's decline of -15.4%. The Zacks analyst believes that suspension of Russian operations amid the ongoing Ukraine war is expected to affect both the company's revenues and non-IFRS operating profit in the near term.
Weak uptake of software licenses and support offerings remains a headwind. Stiff competition and increasing costs to enhance cloud-based offerings is likely to exert pressure on the company's profitability as well.
However, SAP's performance is gaining from strength in its cloud business, especially the new Rise with SAP solution. Momentum in SAP's Business Process Intelligence platform, particularly the S/4HANA solutions along with steady traction witnessed in SuccessFactors Employee Central, Ariba and Fieldglass, Qualtrics and other cloud-based offerings is noteworthy.
(You can read the full research report on SAP here >>>)
Shares of CSX have declined -13.6% over the past year against the Zacks Transportation – Rail industry's decline of -9.4%. The Zacks analyst believes that supply-chain disturbances are hurting the company's operations. Weakness in the merchandise segment due to lower automotive volumes is concerning. High costs, primarily due to escalating fuel expenses, pose a threat to CSX's bottom line. CSX's high capital expenditures are also worrisome.
However, CSX is benefiting from higher export coal volumes, domestic intermodal shipments and favorable pricing. With the demand scenario expected to remain strong, despite the current market bloodbath, management anticipates double-digit growth in operating income and revenues for 2022 from the respective year-ago reported figures.
(You can read the full research report on CSX here >>>)
Other noteworthy reports we are featuring today include Alnylam Pharmaceuticals, Inc., and NVR, Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.